but the HTN market didn't reach that point after the first pretty effective drug was approved. Once you had multiple drugs in multiple classes even then there was innovation - ARBs aren't any more effective than ACE inhibitors, but they became mega blockbusters simply because of the adverse event profile (ARB = no risk of cough basically) so my point is that unless VKTX has a perfect drug, there is going to be room to innovate and still reap huge rewards given the massive size of the market Maybe VKTX will look at a FDC w a FXR agonist? HIV is another good example where you can go from *very* good to even better - both on efficacy w Integrase inhibitors and safety w TDF vs TAF
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.